TNNT2 and cardiomyopathy: Two large studies confirmed that levels of hs-cTnT above the upper reference limit of 14 ng/L can predict the development of cardiomyopathy, indicating a 2- to 3.6-fold increased risk in patients undergoing trastuzumab treatment [11,19].